Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2009. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of share ownership changes and does not contain financial performance data.
Material Changes
The material change reported is the acquisition of Ordinary shares by eight individuals under the Company's Share Reward Plan on April 9, 2009. The transactions involved purchases at a price of £10.10 per share. Each individual acquired 13 shares through the partnership element (personal contribution) and 13 shares through the matching element (Company contribution).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the statutory notification of the share transactions described above.
Investor Verification Points
- Verify the share price of £10.10 per Ordinary share on April 9, 2009.
- Confirm the total number of shares acquired by each listed director (26 shares per person: 13 personal, 13 matched).
- Review the specific terms of the Company's Share Reward Plan to understand the matching mechanism.
- Check subsequent filings for any further changes in director shareholdings.